Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
- PMID: 19165197
- PMCID: PMC2634718
- DOI: 10.1038/sj.bjc.6604867
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
Abstract
A deficient mismatch repair system (dMMR) is present in 10-20% of patients with sporadic colorectal cancer (CRC) and is associated with a favourable prognosis in early stage disease. Data on patients with advanced disease are scarce. Our aim was to investigate the incidence and outcome of sporadic dMMR in advanced CRC. Data were collected from a phase III study in 820 advanced CRC patients. Expression of mismatch repair proteins was examined by immunohistochemistry. In addition microsatellite instability analysis was performed and the methylation status of the MLH1 promoter was assessed. We then correlated MMR status to clinical outcome. Deficient mismatch repair was found in only 18 (3.5%) out of 515 evaluable patients, of which 13 were caused by hypermethylation of the MLH1 promoter. The median overall survival in proficient MMR (pMMR), dMMR caused by hypermethylation of the MLH1 promoter and total dMMR was 17.9 months (95% confidence interval 16.2-18.8), 7.4 months (95% CI 3.7-16.9) and 10.2 months (95% CI 5.9-19.8), respectively. The disease control rate in pMMR and dMMR patients was 83% (95% CI 79-86%) and 56% (30-80%), respectively. We conclude that dMMR is rare in patients with sporadic advanced CRC. This supports the hypothesis that dMMR tumours have a reduced metastatic potential, as is observed in dMMR patients with early stage disease. The low incidence of dMMR does not allow drawing meaningful conclusions about the outcome of treatment in these patients.
Figures
Similar articles
-
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. J Natl Cancer Inst. 2011. PMID: 21597022 Free PMC article.
-
Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.Cancer Sci. 2011 Sep;102(9):1706-11. doi: 10.1111/j.1349-7006.2011.02009.x. Epub 2011 Jul 12. Cancer Sci. 2011. PMID: 21679278
-
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.Med Oncol. 2010 Dec;27(4):1277-85. doi: 10.1007/s12032-009-9374-x. Epub 2009 Dec 1. Med Oncol. 2010. PMID: 19949897
-
Microsatellite instability testing and its role in the management of colorectal cancer.Curr Treat Options Oncol. 2015 Jul;16(7):30. doi: 10.1007/s11864-015-0348-2. Curr Treat Options Oncol. 2015. PMID: 26031544 Free PMC article. Review.
-
[Recent results of irinotecan therapy in colorectal cancer].Magy Onkol. 2004;48(4):281-8. Epub 2005 Jan 17. Magy Onkol. 2004. PMID: 15655572 Review. Hungarian.
Cited by
-
Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers.JCO Precis Oncol. 2019 Mar 8;3:PO.18.00213. doi: 10.1200/PO.18.00213. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32914008 Free PMC article.
-
Fusobacterium nucleatum Infection in Colorectal Cancer: Linking Inflammation, DNA Mismatch Repair and Genetic and Epigenetic Alterations.J Anus Rectum Colon. 2018;2(2):37-46. doi: 10.23922/jarc.2017-055. Epub 2018 Apr 25. J Anus Rectum Colon. 2018. PMID: 30116794 Free PMC article.
-
The Prognostic Impact of Microsatellite Instability on the Outcome of Appendiceal Adenocarcinoma: a National Cancer Database Analysis.J Gastrointest Surg. 2023 Feb;27(2):354-362. doi: 10.1007/s11605-023-05586-z. Epub 2023 Jan 17. J Gastrointest Surg. 2023. PMID: 36650414
-
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.Lancet Oncol. 2022 May;23(5):659-670. doi: 10.1016/S1470-2045(22)00197-8. Epub 2022 Apr 12. Lancet Oncol. 2022. PMID: 35427471 Free PMC article. Clinical Trial.
-
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.Oncologist. 2010;15(4):390-404. doi: 10.1634/theoncologist.2009-0233. Epub 2010 Mar 29. Oncologist. 2010. PMID: 20350999 Free PMC article. Review.
References
-
- Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR (1993) Clues to the pathogenesis of familial colorectal cancer. Science 260: 812–816 - PubMed
-
- Arnold CN, Goel A, Boland CR (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106: 66–73 - PubMed
-
- Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S, Rossi G, Ponti G, Santini A, Losi L, Di GC, Oliani C, Ponz De LM, Lanza G (2005) Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 11: 8332–8340 - PubMed
-
- Bettstetter M, Dechant S, Ruemmele P, Grabowski M, Keller G, Holinski-Feder E, Hartmann A, Hofstaedter F, Dietmaier W (2007) Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res 13: 3221–3228 - PubMed
-
- Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248–5257 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical